Skip to main content
Clinical Trials/NCT07741201
NCT07741201Not yet recruitingNot Applicable

An Adaptive Psychological Intervention to Improve Pain and Reduce Opioid Use Following an Injury

Henry Ford Health System0 sites80 target enrollmentStarted: March 1, 2027Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
80
Primary Endpoint
Opioid use

Study Overview

Brief Summary

The goal of this proposed project is to optimize the adaptive psychological intervention and assess the feasibility and acceptability. The long-term objective of this line of research is to evaluate whether an adaptive psychological intervention delivered after a musculoskeletal injury is effective in preventing the development of chronic pain and long-term opioid use.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Admitted to Henry Ford Hospital
  • •Has an acute musculoskeletal injury
  • •Prescribed opioids during the admission

Exclusion Criteria

  • •Under age 18
  • •Cognitive impairment (i.e., diagnosis of delirium, dementia, or traumatic brain injury/Glasgow Coma Scale less than 13)
  • •Chronic pain condition (i.e., pain most of the day, nearly every day for the past 3 months or longer)
  • •Taking opioids 30 days or more prior to this hospitalization

Arms & Interventions

Subgroup 3

Experimental

Participants who were randomized to the computerized brief intervention but were no longer on opioids 10 days post-baseline and did not receive any further treatment.

Intervention: Computerized brief intervention (Behavioral)

Subgroup 4

Experimental

Participants who were randomized to the computerized brief intervention and were still on opioids 10 days post-baseline and were then randomized to receive the recommendations for the opioid taper.

Intervention: Computerized brief intervention (Behavioral)

Subgroup 4

Experimental

Participants who were randomized to the computerized brief intervention and were still on opioids 10 days post-baseline and were then randomized to receive the recommendations for the opioid taper.

Intervention: Opioid taper recommendations (Behavioral)

Subgroup 1

No Intervention

Participants who were not randomized to the computerized brief intervention and were no longer on opioids 10 days post-baseline and did not receive any further treatment.

Subgroup 2

Active Comparator

Participants who were not randomized to the computerized brief intervention but were on opioids 10 days post-baseline and received recommendations for an opioid taper.

Intervention: Opioid taper recommendations (Behavioral)

Subgroup 5

Experimental

Participants who were randomized to the computerized brief intervention and were still on opioids 10 days post-baseline and were then randomized to receive the recommendations for the opioid taper plus additional psychological treatment sessions.

Intervention: Computerized brief intervention (Behavioral)

Subgroup 5

Experimental

Participants who were randomized to the computerized brief intervention and were still on opioids 10 days post-baseline and were then randomized to receive the recommendations for the opioid taper plus additional psychological treatment sessions.

Intervention: Psychological sessions (Behavioral)

Subgroup 5

Experimental

Participants who were randomized to the computerized brief intervention and were still on opioids 10 days post-baseline and were then randomized to receive the recommendations for the opioid taper plus additional psychological treatment sessions.

Intervention: Opioid taper recommendations (Behavioral)

Outcomes

Primary Outcomes

Opioid use

Time Frame: 90-day follow-up

Whether patient was using opioids

Secondary Outcomes

  • Morphine Dose Equivalent (MDE)(90-day follow-up)
  • Presence of chronic pain(90-day follow-up)
  • Pain severity(90-day follow-up)
  • Pain interference(90-day follow-up)
  • Mindfulness(90-day follow-up)
  • Pain acceptance(90-day follow-up)
  • Depression(90-day follow-up)
  • Anxiety(90-day follow-up)
  • Sleep(90-day follow-up)
  • Impact of Events Scale Revised(90-day follow-up)
  • Opioid misuse(90-day follow-up)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Lisa Matero

Associate Scientist

Henry Ford Health System

Similar Trials